Shoulder Innovations Inc. (SI) reported closing of an oversubscribed $42 million series D financing to further advance commercialization and distribution of its integrated Inset system. In addition to functions performed by SI’s humeral short stem, reverse and stemless components the new implant has proven its ability to overcome loosening of the glenoid, one the most challenging procedures to perform during arthroplasty.
Beijing Vas Medical Co. Ltd. raised ¥100 million (US$15M) in an angel financing round as well as obtaining marketing approval from China’s NMPA for its vascular interventional surgery robot. The company plans to use the funds to develop technology, update products, expand its team and make promotions.
Yongrenxin Medical Instrument Co. Ltd. raised nearly $100 million in a series A funding round to build a health platform to treat heart failures. Sinovac Biotech Ltd. led the round.
Mvision AI Oy raised €5.4 million (US$5.8 million) in a post seed funding round to help accelerate the development of its artificial intelligence (AI)-powered automatic segmentation software, which automates and standardizes radiotherapy treatment for patients. Mvision aims to make same day cancer treatment a standard globally. The funding was led by J12 Ventures and Voima Ventures.
Vitestro Holding BV reported raising $12.7 million in series A financing round to develop the world’s first autonomous blood drawing device. This round was led by Sonder Capital Inc., alongside existing investors and new angel investors with experience in the clinical laboratory and med-tech industry. “Thanks to this fundraising, we are going to accelerate the product development, prepare EU marketing authorization, and initiate production,” Toon Overbeeke, CEO and co-founder of Vitestro, explains to BioWorld.
Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20 million that will see the company build out an oncology drug discovery pipeline derived from its AI proteomics platform.
Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20 million that will see the company build out an oncology drug discovery pipeline derived from its AI proteomics platform.
Seamless Therapeutics GmbH raised $12.5 million in seed financing to take forward a novel gene editing technology based on reprogramming recombinase enzymes.
Doctorly GmbH raised $10 million in a series A funding round to revamp the German health care sector, giving medical staff new tools to eliminate disk operating systems (DOS).
RSS
